View in EDS

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.

Saved in:
Bibliographic Details
Title: Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Authors: Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: dranwaarsaeed1@gmail.com., Park R; Division of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Dai J; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA., Al-Rajabi R; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Kasi A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Baranda J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Williamson S; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Saeed A; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA., Ripp J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA., Collins Z; Department of Radiology, Kansas University Medical Center, Kansas City, KS 66160, USA., Mulvaney K; Kansas University Cancer Center, Kansas City, KS 66205, USA., Shugrue M; Kansas University Cancer Center, Kansas City, KS 66205, USA., Firth-Braun J; Kansas University Cancer Center, Kansas City, KS 66205, USA., Godwin AK; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA., Madan R; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA., Phadnis M; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA., Sun W; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
Source: Cell reports. Medicine [Cell Rep Med] 2023 Feb 21; Vol. 4 (2), pp. 100916. Date of Electronic Publication: 2023 Jan 25.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2023.100916